keyword
MENU ▼
Read by QxMD icon Read
search

docetaxel

keyword
https://www.readbyqxmd.com/read/29456721/combined-treatment-with-d-allose-docetaxel-and-radiation-inhibits-the-tumor-growth-in-an-in-vivo-model-of-head-and-neck-cancer
#1
Hiroshi Hoshikawa, Kazuyo Kamitori, Kanako Indo, Terushige Mori, Mizuna Kamata, Tomoko Takahashi, Masaaki Tokuda
The present study was designed to evaluate the effect of one rare sugar, D-allose, on normal human cells and cutaneous tissue, and to investigate the radiosensitizing and chemosensitizing potential of D-allose in an in vivo model of head and neck cancer. Results indicated that D-allose did not inhibit the growth of normal human fibroblasts TIG-1 cells, and no apoptotic changes were observed after D-allose and D-glucose treatment. The mRNA expression levels of thioredoxin interacting protein (TXNIP) in TIG-1 cells after D-allose treatment increased by 2-fold (50...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29455418/preoperative-chemotherapy-with-docetaxel-cisplatin-and-5-fluorouracil-for-locally-advanced-esophageal-carcinosarcoma-a-case-report-and-review-of-the-literature
#2
Tomoko Yoshimoto, Shinichiro Kobayashi, Kengo Kanetaka, Kazuma Kobayashi, Yasuhiro Nagata, Michi Morita, Yuriko Isagawa, Naoe Kinoshita, Mitsuhisa Takatsuki, Susumu Eguchi
BACKGROUND: Esophageal carcinosarcoma is a relatively rare malignant neoplasm composed of both epithelial carcinomatous and mesenchymal sarcomatous elements. There is no recommended clinical treatment for esophageal carcinosarcoma because of the rarity of the disease. This report describes a case of esophageal carcinosarcoma that was effectively treated with docetaxel, cisplatin, and 5-fluorouracil as preoperative chemotherapy. CASE PRESENTATION: A 73-year-old man had a chief complaint of dysphagia with epigastric pain...
February 17, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29449897/atezolizumab-feasible-second-line-therapy-for-patients-with-non-small-cell-lung-cancer-a-review-of-efficacy-safety-and-place-in-therapy
#3
REVIEW
Fanny Jean, Pascale Tomasini, Fabrice Barlesi
Advanced non-small cell lung cancer (NSCLC) prognosis is still poor and has recently been reformed by the development of immune checkpoint inhibitors and the approval of anti-PD-1 (programmed cell-death 1) treatments such as nivolumab and pembrolizumab in second line. More recently, atezolizumab (MDPL 3280A), a programmed cell-death-ligand 1 (PD-L1) inhibitor, was also studied in this setting. Here, we report a review of the literature assessing the efficacy, safety, and place of atezolizumab in the second-line treatment of advanced NSCLC...
December 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29449773/potential-breast-anticancer-drug-targets-revealed-by-differential-gene-regulatory-network-analysis-and-molecular-docking-neoadjuvant-docetaxel-drug-as-a-case-study
#4
Adel Aloraini, Karim M ElSawy
Understanding gene-gene interaction and its causal relationship to protein-protein interaction is a viable route for understanding drug action at the genetic level, which is largely hindered by inability to robustly map gene regulatory networks. Here, we use biological prior knowledge of family-to-family gene interactions available in the KEGG database to reveal individual gene-to-gene interaction networks that underlie the gene expression profiles of 2 cell line data sets, sensitive and resistive to neoadjuvant docetaxel breast anticancer drug...
2018: Cancer Informatics
https://www.readbyqxmd.com/read/29448072/a-phase-iii-study-comparing-sb3-a-proposed-trastuzumab-biosimilar-and-trastuzumab-reference-product-in-her2-positive-early-breast-cancer-treated-with-neoadjuvant-adjuvant-treatment-final-safety-immunogenicity-and-survival-results
#5
X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, J-H Ahn, S-A Im, T Sarosiek, S Chatterjee, M Z Wojtukiewicz, Y Shparyk, V Moiseyenko, M Bello, V Semiglazov, Y Lee, J Lim
BACKGROUND: The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanced human epidermal growth factor receptor 2-positive breast cancer was demonstrated in the previous report. Here, we report the final safety, immunogenicity and survival results after neoadjuvant-adjuvant treatment. PATIENTS AND METHODS: Patients were randomised 1:1 to receive neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide)...
February 12, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29447469/tricin-isolated-from-allium-atroviolaceum-potentiated-the-effect-of-docetaxel-on-pc3-cell-proliferation-role-of-mir-21
#6
Sorayya Ghasemi, Zahra Lorigooini, JokoPriyanto Wibowo, Hossein Amini-Khoei
For more effectiveness and overcoming the drug resistance Chemotherapy agents, the combination treatment is raised. Flavonoids with different anti-cancer effects are an appropriate choice as lead compounds. Over expressed MiR-21 in prostate cancer is associated with metastasis and drug resistance to chemotherapy with Docetaxel. In this study, the anticancer effect of 4', 5, 7-Trihydroxy-3', 5'-dimethoxyflavone (Tricin) was investigated with Docetaxel on PC3 cell line. Tricin was initially isolated from the Allium atroviolaceum by column chromatography and recrystallization method...
February 15, 2018: Natural Product Research
https://www.readbyqxmd.com/read/29440919/efficacy-and-safety-of-cox-2-inhibitors-for-advanced-non-small-cell-lung-cancer-with-chemotherapy-a-meta-analysis
#7
Ping Dai, Jing Li, Xiao-Ping Ma, Jian Huang, Juan-Juan Meng, Ping Gong
Background: The study of cyclooxygenase-2 (COX-2) inhibitors is now mired in controversy. We performed a meta-analysis to assess the efficacy and safety profile of COX-2 inhibitors in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: A literature search of PubMed, EMBASE, the Cochrane Central databases, and ClinicalTrials.gov, up until March 26, 2017, identified relevant randomized controlled trials. Data analysis was performed using Stata 12...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29436875/synthesis-in-vitro-characterization-and-anti-tumor-effects-of-novel-polystyrene-poly-amide-ether-ester-imide-co-polymeric-micelles-for-delivery-of-docetaxel-in-breast-cancer-in-balb-c-mice
#8
Jaleh Varshosaz, Saeede Enteshari, Farshid Hassanzadeh, Batool Hashemi-Beni, Mohsen Minaiyan, Razieh Mirsafaei
OBJECTIVE: the goal of the present work was to make novel co-polymeric micellar carriers for the delivery of docetaxel (DTX). SIGNIFICANCE: Co-polymeric micelles can not only solubilize DTX and eliminate the need for toxic surfactants to dissolve it, but also cause passive targeting of the drug to the tumor and reduce its toxic side effects. METHODS: Poly (styrene-maleic acid) (SMA) was conjugated to poly (amide-ether-ester-imide)-poly ethylene glycol (PAEEI-PEG)...
February 13, 2018: Drug Development and Industrial Pharmacy
https://www.readbyqxmd.com/read/29435291/efficacy-and-safety-of-doceaqualip-in-a-patient-with-locally-advanced-cervical-cancer-a-case-report
#9
Rammohan Prasanna, Deepak Bunger, Mujtaba A Khan
The standard of care for locally advanced cervical cancer has been the combination of a taxane with platinum based therapy. Conventional docetaxel is known to cause hypersensitivity reactions, fluid retention and other toxicities due to polysorbate-80 and ethanol. Corticosteroid premedication prior to docetaxel administration is required to prevent these toxicities, however, toxicities are still observed, sometimes fatal, despite premedication. DoceAqualip, a nanosomal docetaxel lipid suspension, developed with lipids generally regarded as safe (GRAS) by the US Food and Drug Administration, is devoid of polysorbate-80 and ethanol...
February 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29435149/mir-361-5p-suppresses-chemoresistance-of-gastric-cancer-cells-by-targeting-foxm1-via-the-pi3k-akt-mtor-pathway
#10
Lei Tian, Zhifeng Zhao, Ling Xie, JinPeng Zhu
Gastric cancer is a prevalent cancer and chemotherapy is a main treatment for patients. Docetaxel is commonly used as a chemotherapeutic drug for gastric cancer patients. With the increasing emergence of docetaxel resistance, exploring the mechanism of chemoresistance may improve prognosis of patients. In this study, we found that overexpressed miR-361-5p suppressed chemoresistance to docetaxel of gastric cancer cells (SGC-7901, MKN-28) by decreasing IC 50 values of docetaxel while increasing cell apoptosis rate, especially in docetaxel resistant SGC-7901 cells...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29434663/natural-history-of-castration-resistant-prostate-cancer-in-sub-saharan-african-black-men-a-single-centre-study-of-nigerian-men
#11
REVIEW
Jibril O Bello
Purpose: Native sub-Saharan African black men (SSBM) are disproportionately impacted by higher stage and incurable forms of prostate cancer (PCa). This study evaluates the natural history and survival of a cohort of SSBM with castration-resistant prostate cancer (CRPC). Methods: A retrospective study of patients with CRPC as defined by the Prostate Cancer Working Group 2 managed at a centre in sub-Saharan Africa between January 2011 and December 2015 was conducted...
2018: Ecancermedicalscience
https://www.readbyqxmd.com/read/29433060/dual-tumor-targeted-multifunctional-magnetic-hyaluronic-acid-micelles-for-enhanced-mr-imaging-and-combined-photothermal-chemotherapy
#12
Shaohui Zheng, Jiwon Han, Zhen Jin, Chang-Sei Kim, Sukho Park, Kyu-Pyo Kim, Jong-Oh Park, Eunpyo Choi
Multifunctional polymeric micelles were developed as a promising dual tumor-targeted drug delivery platform for magnetic resonance (MR) imaging and combined photothermal-chemotherapy. HA-C16 copolymers were synthesized via peptide formation process with subsequent co-encapsulation of therapeutic agent docetaxel (DTX) and superparamagnetic iron oxide nanoparticles (SPIONs) to form the multifunctional micelles. The micelles exhibited uniform nanosize and remarkable colloidal stability in aqueous solution. The sustained drug release behavior from HA micelles was observed over the test period...
February 5, 2018: Colloids and Surfaces. B, Biointerfaces
https://www.readbyqxmd.com/read/29431540/pharmacokinetic-pharmacodynamic-drug-evaluation-of-enzalutamide-for-treating-prostate-cancer
#13
Jeong Hee Hong
Enzalutamide is the first approved second-generation androgen receptor (AR) antagonist in the treatment of metastatic castration-resistant prostate cancer (mCRPC) with or without docetaxel-based chemotherapy. Over the past 5 years, a number of attempts were made to determine the efficacy of enzalutamide in the different clinical settings. Areas covered: A literature search was performed at the PubMed, Embase, and Web of Science database to collect the most relevant and impactful studies, including basic science investigations, clinical trials, and reviews...
February 12, 2018: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/29429804/clinical-outcome-of-prostate-cancer-patients-with-germline-dna-repair-mutations-retrospective-analysis-from-an-international-study
#14
Joaquin Mateo, Heather H Cheng, Himisha Beltran, David Dolling, Wen Xu, Colin C Pritchard, Helen Mossop, Pasquale Rescigno, Raquel Perez-Lopez, Verena Sailer, Michael Kolinsky, Ada Balasopoulou, Claudia Bertan, David M Nanus, Scott T Tagawa, Heather Thorne, Bruce Montgomery, Suzanne Carreira, Shahneen Sandhu, Mark A Rubin, Peter S Nelson, Johann S de Bono
BACKGROUND: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear. OBJECTIVE: To determine whether gDDRm status impacts benefit from established therapies in mPC. DESIGN, SETTING, AND PARTICIPANTS: This is a retrospective, international, observational study. Medical records were reviewed for 390 mPC patients with known gDDRm status...
January 29, 2018: European Urology
https://www.readbyqxmd.com/read/29429514/culturing-substrates-influence-the-morphological-mechanical-and-biochemical-features-of-lung-adenocarcinoma-cells-cultured-in-2d-or-3d
#15
Adriele Prina-Mello, Namrata Jain, Baiyun Liu, Jason I Kilpatrick, Melissa A Tutty, Alan P Bell, Suzanne P Jarvis, Yuri Volkov, Dania Movia
Alternative models such as three-dimensional (3D) cell cultures represent a distinct milestone towards capturing the realities of cancer biology in vitro and reduce animal experimentation in the preclinical stage of drug discovery. Significant work remains to be done to understand how substrates used in in vitro alternatives influence cancer cells phenotype and drug efficacy responses, so that to accurately link such models to specific in vivo disease scenarios. Our study describes how the morphological, mechanical and biochemical properties of adenocarcinoma (A549) cells change in response to a 3D environment and varying substrates...
February 2018: Tissue & Cell
https://www.readbyqxmd.com/read/29426250/%C3%AE-conotoxin-imi-modified-polymeric-micelles-as-potential-nanocarriers-for-targeted-docetaxel-delivery-to-%C3%AE-7-nachr-overexpressed-non-small-cell-lung-cancer
#16
Dong Mei, Libo Zhao, Binlong Chen, Xiaoyan Zhang, Xiaoling Wang, Zhiying Yu, Xin Ni, Qiang Zhang
A micelle system modified with α-Conotoxin ImI (ImI), a potently antagonist for alpha7 nicotinic acetylcholine receptor (α7-nAChR) previously utilized for targeting breast cancer, was constructed. Its targeting efficiency and cytotoxicity against non-small cell lung cancer (NSCLC) highly expressing α7-nAChR was investigated. A549, a non-small cell lung cancer cell line, was selected as the cell model. The cellular uptake study showed that the optimal modification ratio of ImI on micelle surface was 5% and ImI-modification increased intracellular delivery efficiency to A549 cells via receptor-mediated endocytosis...
November 2018: Drug Delivery
https://www.readbyqxmd.com/read/29426226/the-shape-of-nanoparticles-as-a-design-parameter-to-improve-docetaxel-antitumor-efficacy
#17
Yifei Guo, Shuang Zhao, Hanhong Qiu, Ting Wang, Yanna Zhao, Meihua Han, Zhengqi Dong, Xiangtao Wang
It was reported that the shape of nanocarriers played an important role in achieving better therapeutic effect. To optimize the morphology and enhance the antitumor efficacy, in this study based on the amphiphilic PAMAM-b-OEG codendrimer (POD), docetaxel-loaded spherical and flake-like nanoparticles (DTX nanospheres and nanosheets) were prepared via antisolvent precipitation method with the similar particle size, surface charge, stability, and release profiles. The feed weight ratio of DTX/POD and the branched structure of OEG dendron were suggested to influence on the shapes of the self-assembled nanostructures...
February 9, 2018: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/29424297/use-of-immunotherapy-to-treat-metastatic-breast-cancer
#18
Andrea Nicolini, Vivian Barak, Piermario Biava, Paola Ferrari, Giuseppe Rossi, Angelo Carpi
This article reviews the principal attempts of immune-modulation or immune therapy in metastatic breast cancer. It considers their rationale and reports on results from the relevant key clinical trials. Immune-modulatory or immune-stimulating cytokines used alone or combined with conventional therapies is among the principal approaches of immune manipulation in breast cancer. As this issue was recently reviewed by us, the aim of the current article is to discuss our updated and unpublished data on this topic...
February 9, 2018: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29423118/the-efficacy-and-safety-of-anti-pd-1-pd-l1-antibody-therapy-versus-docetaxel-for-pretreated-advanced-nsclc-a-meta-analysis
#19
Guanghong Huang, Xin Sun, Dapeng Liu, Yunfeng Zhang, Boxiang Zhang, Guodong Xiao, Xiang Li, Xiao Gao, Chenhao Hu, Meng Wang, Hong Ren, Sida Qin
Antibodies against the immune checkpoint proteins PD-1 and PD-L1 are novel therapeutic drugs for the treatment of advanced non-small cell lung cancer (NSCLC). Many clinical trials involving these drugs achieved breakthroughs in patients previously treated for advanced NSCLC. However, the results of these clinical studies are not consistent. In this report, we performed a meta-analysis to assess the efficacy and safety of anti-PD-1/PD-L1 antibodies compared with docetaxel treatment for advanced NSCLC patients from 5 randomized clinical trials...
January 9, 2018: Oncotarget
https://www.readbyqxmd.com/read/29423090/efficacy-of-assessing-circulating-cell-free-dna-using-a-simple-fluorescence-assay-in-patients-with-triple-negative-breast-cancer-receiving-neoadjuvant-chemotherapy-a-prospective-observational-study
#20
Kwonoh Park, Miyoung Woo, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Jin Roh, Gyungyub Gong, Sung-Bae Kim
This study aims to assess cell-free DNA (CFD) by a fluorescence assay as a biomarker for early prediction of a pathologic complete response (pCR) and relapse in patients with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy. Patients with clinical stage II or III TNBC scheduled for neoadjuvant chemotherapy were prospectively enrolled. All patients underwent four cycles of Adriamycin plus cyclophosphamide (AC), followed by four cycles of cisplatin or docetaxel chemotherapy and surgery...
January 9, 2018: Oncotarget
keyword
keyword
33993
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"